Life Sciences Tools & Services Q1 2026 Earnings: Illumina, Bruker Lead as 10x Genomics Revenue Declines
核心洞察
Illumina reported Q1 revenues of $1.09 billion, up 4.8% year-on-year, beating analyst expectations and raising full-year EPS guidance.
Bruker (搜索) delivered $823.4 million in revenue, a 2.7% increase, surpassing analyst estimates across revenue, EPS, and organic growth metrics.
10x Genomics (搜索) posted $150.8 million in revenue, a 2.6% year-on-year decline, representing the slowest revenue growth among its peer group.
The first quarter of 2026 painted a mixed picture for the life sciences tools and services sector, with industry leaders Illumina and Bruker (搜索) posting strong beats while 10x Genomics (搜索) and Azenta (搜索) faced headwinds. The earnings season highlighted diverging trajectories among companies that supply the critical infrastructure underpinning pharmaceutical R&D and genomic research.
Illumina Surpasses Expectations with Strong Guidance
Illumina (NASDAQ:ILMN), the pioneer in high-throughput DNA sequencing, reported Q1 revenues of $1.09 billion, representing a 4.8% increase year-on-year. The figure topped analysts' expectations by 1.8%, marking a strong start to the fiscal year.
Beyond the revenue beat, Illumina delivered an impressive beat of analysts' full-year EPS guidance estimates, signaling management confidence in sustained performance through 2026. The company also surpassed analysts' EPS estimates for the quarter itself. Investor enthusiasm has been pronounced, with the stock climbing 52.9% since reporting, trading at $193.74 at the time of analysis.
Bruker (搜索) Delivers Across All Metrics
Bruker (搜索) (NASDAQ:BRKR), with its legacy in nuclear magnetic resonance technology and high-performance scientific instruments, reported revenues of $823.4 million, up 2.7% year-on-year. This result beat analysts' expectations by 3.4%.
The quarter was characterized as very strong, with Bruker (搜索) also recording a beat of analysts' EPS estimates and a solid beat of analysts' organic revenue estimates. The market response has been the most dramatic among peers, with the stock surging 54.2% since reporting to trade at $58.63.
10x Genomics (搜索) Faces Revenue Contraction
10x Genomics (搜索) (NASDAQ:TXG), founded in 2012 to advance single-cell and spatial biology research, reported revenues of $150.8 million, down 2.6% year-on-year. Despite the decline, the print beat analysts' expectations by 2.9%, and the company logged a beat of analysts' EPS estimates.
However, 10x Genomics (搜索) recorded the slowest revenue growth among its peer group, underscoring challenges in its core markets for single-cell resolution instruments, consumables, and software. The stock has nonetheless rallied 80.6% since reporting, trading at $40.50.
Azenta (搜索): The Weakest Q1 Performance
Azenta (搜索) (NASDAQ:AZTA), which provides biological sample management, storage, and genomic services to pharmaceutical and biotechnology companies, reported revenues of $144.8 million, flat year-on-year. The result fell short of analysts' expectations by 2.5%.
The quarter was described as disappointing, with a significant miss of analysts' EPS estimates. Despite the underperformance, the stock has edged up approximately 3-4% since results, trading around $25.50.
Agilent and West Pharmaceutical Services
Agilent Technologies (搜索) (NYSE:A) reported revenues of $1.84 billion, up 10% year-on-year, surpassing analysts' expectations by 1.9%. The company also beat full-year EPS guidance estimates, though it had the weakest guidance update among its peers. The stock is up 12.8% since reporting, trading at $130.71.
West Pharmaceutical Services stood out with the biggest analyst estimate beat and the highest full-year guidance raise among its peers, with its stock up approximately 30% since reporting to trade near $357.
Market Context
The earnings results arrived against a backdrop of shifting investor sentiment. Late 2025 into early 2026 saw concerns around artificial intelligence disrupting software and crypto markets, triggering a rotation toward safer havens. By spring 2026, geopolitical risk—specifically the US conflict with Iran—became the dominant driver of market psychology, shifting focus from growth rates to oil supply, inflation, and global stability.